NorthWest Biotherapeutics Inc (NWBO)

[alphapuppy]

The main point being, that this therapy may be useful for a larger number of people when you count both newly diagnosed and recurrent patients. So I'm hoping we get an indication with our Upcoming approval to treat both newly diagnosed and or recurrent patients. And I think we will. The reason is the recurrent Patients have absolutely no standard of care and need this therapy profoundly.. There is no standard of care for recurrent GBM.